US Edition
Type 2 Diabetes Drug Shows Improvements for Patients with Progressive Liver Disease
- From 2018 to 2023, researchers in China conducted a clinical trial to assess the impact of dapagliflozin on individuals with advancing liver conditions who also have type 2 diabetes.
- The study focused on metabolic dysfunction-associated steatohepatitis , a progressive liver condition characterized by fat buildup and fibrosis, with dapagliflozin hypothesized to improve liver outcomes beyond glycemic control.
- Participants who took dapagliflozin showed improvement in fibrosis and steatohepatitis without worsening liver scarring, while those on placebo had lower rates of such improvements.
- Specifically, 45% of dapagliflozin patients improved fibrosis without worsening MASH versus 20% in placebo, and 53% showed MASH improvement without fibrosis worsening compared to 30% on placebo.
- These findings suggest dapagliflozin may have broader therapeutic roles for liver disease, but larger and longer trials are needed to confirm its safety and efficacy across diverse populations.
31 Articles
31 Articles
Clinical trial finds diabetes pill reduces liver scarring
A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH) during a clinical trial in China. Participants on the drug saw better liver outcomes and fewer side effects than those on a placebo. Although more research is needed, especially in div…
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
Non-alcoholic steatohepatitis is frequently associated with diabetes and may cause progressive liver disease. Current treatment options are limited. Here we report on a prospective, randomised, double-blind, placebo-controlled trial of two doses of HTD1801 (berberine ursodeoxycholate, an ionic salt of berberine and ursodeoxycholic acid), versus placebo that was conducted in 100 subjects with fatty liver disease and diabetes (NCT03656744). Treatm…
Newsbug.info
Diabetes Drug Effective For Fatty Liver Disease
Key Takeaways
Type 2 diabetes drug shows improvements for patients with progressive liver disease
The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.
MedPage Today
Anti-Aging, Acupuncture and Health NewsSGLT2 Inhibitor Shows Promise as MASH Treatment
(MedPage Today) -- An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 diabetes, a randomized trial in China found. In 154 adults with biopsy-diagnosed MASH, improvement without...
Coverage Details
Bias Distribution
- 53% of the sources are Center
To view factuality data please Upgrade to Premium
